AAV2

AAV2. Adeno-associated virus 2 is a small, non-enveloped virus belonging to the genus Dependoparvovirus within the family Parvoviridae. It was one of the first serotypes identified and has become a foundational tool in molecular biology and a critical vector in the development of modern gene therapy. Its replication is dependent on co-infection with a helper virus, such as adenovirus or herpes simplex virus.

Structure and Genome

The viral capsid is an icosahedral structure approximately 26 nanometers in diameter, composed of three viral proteins: VP1, VP2, and VP3. This protein shell encases a linear, single-stranded DNA genome of about 4.7 kilobases. The genome is flanked by inverted terminal repeat (ITR) sequences that form characteristic T-shaped hairpin structures essential for DNA replication and genome packaging. The internal genome contains two main open reading frames: *rep*, encoding non-structural proteins for replication and integration, and *cap*, encoding the structural capsid proteins. This compact genetic organization was extensively characterized by researchers at the University of Florida and the National Institutes of Health.

Serotype and Tropism

As the prototype member of the adeno-associated virus family, its surface topology defines its specific interactions with host cell surface receptors. It primarily binds to heparan sulfate proteoglycan (HSPG) as its primary attachment receptor, a discovery made by scientists at the University of Pennsylvania. This interaction is followed by binding to coreceptors such as αVβ5 integrin, fibroblast growth factor receptor 1 (FGFR1), and hepatocyte growth factor receptor (c-Met) for cellular entry. This receptor profile confers a broad but distinct tropism, favoring cell types including skeletal muscle, neurons, retinal pigment epithelium, and hepatocytes. Its transduction efficiency varies significantly across different tissues and species, influencing its application scope.

Applications in Gene Therapy

It serves as a leading viral vector for delivering therapeutic transgenes due to its non-pathogenic nature and ability to establish long-term gene expression. The first approved gene therapy in the Western world, Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency, utilized a vector derived from this serotype. It has been central to clinical trials for treating inherited retinal diseases, such as those conducted by Spark Therapeutics leading to Luxturna (voretigene neparvovec). Major research institutions, including the Children's Hospital of Philadelphia and University College London, have employed it in experimental therapies for hemophilia B and Parkinson's disease.

Production and Vector Engineering

Manufacturing recombinant vectors involves transfection of adherent cell lines, like HEK293 cells, with a plasmid system containing the vector genome and helper functions. This process is often scaled in bioreactors by companies such as Oxford Biomedica and Brammer Bio. Significant vector engineering efforts have focused on creating hybrid capsids through directed evolution or rational design to alter tropism and evade neutralizing antibodies. Pioneering work at the California Institute of Technology and University of North Carolina at Chapel Hill has produced chimeric vectors with enhanced transduction for specific targets like the central nervous system and heart.

Safety and Immunogenicity

It is considered one of the safest viral vectors, with no known association with human disease. However, host immune responses remain a significant consideration. Pre-existing neutralizing antibodies from natural exposure can limit transduction efficacy, a challenge addressed in studies by the Allen Institute for Immunology. The vector can also trigger a capsid-specific T-cell response that may eliminate transduced cells, as observed in early trials for hemophilia at University College London. Strategies to mitigate immunogenicity include using empty capsid decoys, engineering immune stealth capsids, and employing transient immunosuppression protocols developed at institutions like the Fred Hutchinson Cancer Research Center.

Category:Viruses Category:Gene therapy Category:Virology